ArticleNPJ precision oncology2026

Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.

Arvid Cederlund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.